Welcome to our dedicated page for SCIENTIFIC INDUSTRIES SEC filings (Ticker: SCND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scientific Industries, Inc. filings document the company’s life science tool operations, governance matters and material events tied to its continuing DOTS bioprocessing, VIVID pill counter and Torbal businesses. Recent 8-K and amended 8-K filings cover the completed sale of the Genie Division assets, related pro forma financial information, transition and supply arrangements, and a change in the company’s independent registered public accounting firm.
Proxy filings describe annual meeting voting matters and shareholder governance procedures. Periodic-report notices and Form 10-Q-related disclosures address reporting timing, financial-statement preparation and the company’s formal public-company reporting obligations.
SCIENTIFIC INDUSTRIES INC (SCND) reported that Chairman of the Board and director John A. Moore purchased 5,000 shares of Common Stock on August 20, 2026 at $0.76 per share in a purchase described as an open-market or private transaction. Following this transaction, he directly holds 950,641 shares.
SCIENTIFIC INDUSTRIES INC (SCND) reported an insider share purchase by Chairman of the Board John A. Moore. On 2026-08-20, he purchased 14,700 shares of Common Stock in an open market or private transaction at $0.7112 per share, bringing his directly held stake to 945,641 shares.
Scientific Industries, Inc. reported higher revenue but continued losses for the quarter and six months ended June 30, 2026. Net revenues rose to $1,470,400 for the quarter and $2,697,500 for the six months, up from $1,081,000 and $2,023,300 in 2025, driven mainly by growth in Benchtop Laboratory Equipment and increased Bioprocessing Systems sales.
Gross margin improved to 42.3% for the quarter and 40.5% year-to-date, compared with 34.8% and 35.6% a year earlier, helped by higher-margin DOTS bioprocessing products. Operating expenses fell materially, with six‑month general and administrative costs down to $1,300,900 from $1,774,000 and selling expenses down to $1,334,200 from $1,528,100, reflecting headcount reductions and cost savings.
The company still recorded a six‑month loss from continuing operations of $(2,823,100), improved from $(3,854,900). Cash and cash equivalents were $616,500 and investment securities $3,932,000 at June 30, 2026. Net cash used in operating activities was $(1,897,600), better than $(3,204,500) in 2025. Management expects cash, investments, and proceeds and payments related to the 2025 Genie Division sale to fund operations for at least one year, while acknowledging reliance on expense reductions, revenue growth and potentially additional capital.
Scientific Industries Inc. received an amended ownership report from Laurence W. Lytton and the Lytton-Kambara Foundation. Lytton reports beneficial ownership of 1,226,104 shares of common stock, or 9.9% of the class, including 881,386 shares and warrants to purchase 1,380,000 shares, all subject to a 9.99% beneficial ownership limitation. The Lytton-Kambara Foundation reports beneficial ownership of 1,245,527 shares, or 9.9%, including 706,386 shares and warrants to purchase 1,220,000 shares, also subject to the same 9.99% limitation. Percentages are calculated using 11,928,599 shares of common stock outstanding as of May 13, 2026.
Scientific Industries Inc. Chairman of the Board and director John A. Moore bought 4,000 shares of Common Stock in an open-market purchase at $0.7113 per share. After this transaction, he directly holds 930,871 shares, making this a relatively small addition to his existing position.
Scientific Industries, Inc. reports first-quarter 2026 results showing higher sales but continued losses as it invests in bioprocessing. Revenue rose to $1,227,100 from $942,300, driven by growth in both Benchtop Laboratory Equipment and Bioprocessing Systems, and gross margin improved to 38.3% from 36.5%.
The loss from continuing operations narrowed to $1,589,300 from $2,057,100, with basic and diluted loss per share improving to $(0.13) from $(0.16), helped by lower general and administrative and selling expenses. Research and development spending increased as new bioprocessing products were developed.
Cash and cash equivalents were $797,800 and investment securities were $4,853,000 as of March 31, 2026. Operating activities used $993,500 of cash in the quarter. Management cites proceeds and follow-on agreements from the 2025 Genie Division sale as support for funding operations for at least one year, while acknowledging an accumulated deficit of $36,740,200 and expected ongoing negative operating cash flows.
Scientific Industries Inc. reported that President and CEO Helena R. Santos received a grant of stock options covering 130,000 shares of common stock on February 17, 2026. The options have an exercise price of $0.60 per share, were granted at no purchase cost, and vest on a 4 year cliff from the grant date. Following this award, Santos holds options on a total of 563,388 shares directly. This is a compensation-related grant rather than an open-market share purchase or sale.
Scientific Industries Inc. reported that President and CEO Helena R. Santos received a grant of stock options to acquire 50,000 shares of common stock. The options carry an exercise price of $0.60 per share, become exercisable starting on February 17, 2027, and expire on February 17, 2036. According to the disclosure, these options were granted in lieu of salary and vest over one year at a rate of 1/12th per month. After this grant, Santos directly holds 433,388 derivative securities related to the company.
Scientific Industries, Inc. reported full-year 2025 results, highlighted by the sale of its Genie benchtop product line and continued investment in bioprocessing. Net revenues rose to $5,053,800, driven mainly by Torbal weighing products, while dependence on a single pill-counter customer remained high.
The company posted a net loss of $1,220,400, a substantial improvement from 2024 as it recorded a $5,263,400 gain on the Genie sale and reduced general, selling, and R&D expenses. However, gross margin fell to 25.8% due to bioprocessing inventory write-offs.
Cash and equivalents were $955,000 at year-end, with an accumulated deficit of $35,150,900. Management expects existing cash plus proceeds and earn-outs from the Genie transaction to fund operations for at least one year while it pursues growth in its Bioprocessing Systems segment.
SCIENTIFIC INDUSTRIES INC Chairman John A. Moore bought additional shares of the company’s stock. On this Form 4, he reports an open-market purchase of 9,000 shares of Common Stock at a price of $0.58 per share on March 23, 2026.
Following this transaction, Moore directly owns 926,871 shares of Scientific Industries common stock. This filing reflects a net increase in his holdings, as there were no reported sales, option exercises, or derivative transactions in this disclosure.